The results of treatment of neurotic disorders with single or divided daily doses of the anxiolytic drug clobazam have been compared. The trial was performed in two groups, each of 57 patients, paired according to age, sex, diagnosis, severity of initial disorder, and total daily dose. The 114 subjects formed a random subgroup from a total of 1369 patients taking part in a postmarketing surveillance trial of clobazam. In view of the changes in the overall severity of the symptoms, in persistent anxiety and anxiety crises, in sleep disorders, the global clinical impression and the tolerance, it is concluded that clobazam is a useful drug in the treatment of anxiety, and that single or divided daily dosage schedules produce similar results.